News und Analysen

EssilorLuxottica has posted impressive half-year results, with currency-adjusted revenue increasing by 7.3% to €14.02 billion, significantly exceeding analyst expectations. The standout performer

Abivax has successfully completed its capital raise of $650 million (€554 million) through the issuance of 10.156 million American Depositary Shares priced at $64 each. The offering, which concluded

The French pharmaceutical giant Sanofi has announced plans to acquire US-based Blueprint Medicines for $9.1 billion, marking a strategic push into the specialized immunology market. The ambitious

The French pharmaceutical giant Sanofi faced a significant blow as its lung medication candidate Itepekimab delivered mixed Phase III trial results. While one of the critical studies showed the drug

Sanofi has made a strategic move to strengthen its neurology portfolio by acquiring Vigil Neuroscience for up to $600 million. The French pharmaceutical giant will pay $470 million ($8 per share)

Sanofi has received FDA approval for Qfitlia, its innovative hemophilia therapy that represents the first antithrombin-lowering treatment for hemophilia A or B patients with or without inhibitors

EssilorLuxottica, the global leader in eyewear and optical products, has demonstrated remarkable financial performance in its latest fiscal year. The Franco-Italian eyewear giant reported a 4.4%

L'Oréal, the French cosmetics giant, has announced a significant restructuring of its investment in pharmaceutical company Sanofi through an off-market block trade. The transaction involves the sale